Towards a better understanding of QT interval variability

Larisa G. Tereshchenko, Ronald D Berger

Research output: Contribution to journalReview article

Abstract

The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline E14 recommends ‘Thorough QT Study’ as a standard assessment of drug-induced QT interval prolongation. At the same time, the value of drug-induced QTc prolongation as a surrogate marker for risk of life-threatening polymorphic ventricular tachycardia known as torsades des pointes remains controversial. Beat-to-beat variability of QT interval was recently proposed as an alternative metric. The following review addresses mechanisms of beat-to-beat QT variability, methods of QT interval variability measurements, and its prognostic value in clinical studies.

Original languageEnglish (US)
Pages (from-to)245-251
Number of pages7
JournalTherapeutic Advances in Drug Safety
Volume2
Issue number6
DOIs
StatePublished - 2011

Fingerprint

Pharmaceutical Preparations
Ventricular Tachycardia
Biomarkers
Guidelines
Clinical Studies

Keywords

  • drug safety
  • QT interval
  • QT variability
  • ventricular tachyarrhythmias

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Towards a better understanding of QT interval variability. / Tereshchenko, Larisa G.; Berger, Ronald D.

In: Therapeutic Advances in Drug Safety, Vol. 2, No. 6, 2011, p. 245-251.

Research output: Contribution to journalReview article

@article{0966cd464ec740d9836610cebb344b63,
title = "Towards a better understanding of QT interval variability",
abstract = "The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline E14 recommends ‘Thorough QT Study’ as a standard assessment of drug-induced QT interval prolongation. At the same time, the value of drug-induced QTc prolongation as a surrogate marker for risk of life-threatening polymorphic ventricular tachycardia known as torsades des pointes remains controversial. Beat-to-beat variability of QT interval was recently proposed as an alternative metric. The following review addresses mechanisms of beat-to-beat QT variability, methods of QT interval variability measurements, and its prognostic value in clinical studies.",
keywords = "drug safety, QT interval, QT variability, ventricular tachyarrhythmias",
author = "Tereshchenko, {Larisa G.} and Berger, {Ronald D}",
year = "2011",
doi = "10.1177/2042098611421209",
language = "English (US)",
volume = "2",
pages = "245--251",
journal = "Therapeutic Advances in Drug Safety",
issn = "2042-0986",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Towards a better understanding of QT interval variability

AU - Tereshchenko, Larisa G.

AU - Berger, Ronald D

PY - 2011

Y1 - 2011

N2 - The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline E14 recommends ‘Thorough QT Study’ as a standard assessment of drug-induced QT interval prolongation. At the same time, the value of drug-induced QTc prolongation as a surrogate marker for risk of life-threatening polymorphic ventricular tachycardia known as torsades des pointes remains controversial. Beat-to-beat variability of QT interval was recently proposed as an alternative metric. The following review addresses mechanisms of beat-to-beat QT variability, methods of QT interval variability measurements, and its prognostic value in clinical studies.

AB - The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline E14 recommends ‘Thorough QT Study’ as a standard assessment of drug-induced QT interval prolongation. At the same time, the value of drug-induced QTc prolongation as a surrogate marker for risk of life-threatening polymorphic ventricular tachycardia known as torsades des pointes remains controversial. Beat-to-beat variability of QT interval was recently proposed as an alternative metric. The following review addresses mechanisms of beat-to-beat QT variability, methods of QT interval variability measurements, and its prognostic value in clinical studies.

KW - drug safety

KW - QT interval

KW - QT variability

KW - ventricular tachyarrhythmias

UR - http://www.scopus.com/inward/record.url?scp=84993683497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993683497&partnerID=8YFLogxK

U2 - 10.1177/2042098611421209

DO - 10.1177/2042098611421209

M3 - Review article

AN - SCOPUS:84993683497

VL - 2

SP - 245

EP - 251

JO - Therapeutic Advances in Drug Safety

JF - Therapeutic Advances in Drug Safety

SN - 2042-0986

IS - 6

ER -